Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Epithelial Cancer Recurrent|Sarcoma|Non-small Cell Lung Cancer|Carcinoma, Transitional Cell|Prostate Cancer|Prostatic Neoplasms
Interventions: DRUG: Mifepristone and Eribulin in combination
Sponsor: Corcept Therapeutics